FY2028 Earnings Forecast for DVAX Issued By William Blair

Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) - Stock analysts at William Blair issued their FY2028 earnings per share (EPS) estimates for Dynavax Technologies in a note issued to investors on Wednesday, June 4th. William Blair analyst M. Phipps forecasts that the biopharmaceutical company will post earnings of $1.18 per share for the year. William Blair has a "Outperform" rating on the stock. The consensus estimate for Dynavax Technologies' current full-year earnings is $0.32 per share.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The firm had revenue of $68.16 million during the quarter, compared to the consensus estimate of $70.01 million.

Several other equities research analysts have also recently weighed in on DVAX. JMP Securities cut their target price on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. The Goldman Sachs Group lowered their price target on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a report on Thursday, April 17th. Wall Street Zen lowered Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. Finally, HC Wainwright reiterated a "buy" rating and issued a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $24.00.

Dynavax Technologies Price Performance

NASDAQ:DVAX traded up $0.29 during mid-day trading on Thursday, reaching $10.24. The stock had a trading volume of 1,408,713 shares, compared to its average volume of 2,197,681. Dynavax Technologies has a 12 month low of $9.22 and a 12 month high of $14.63. The stock has a market capitalization of $1.23 billion, a PE ratio of 56.89 and a beta of 1.06. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The stock has a 50-day simple moving average of $10.71 and a two-hundred day simple moving average of $12.25.

Institutional Trading of Dynavax Technologies

A number of hedge funds have recently added to or reduced their stakes in the stock. Deep Track Capital LP lifted its stake in shares of Dynavax Technologies by 42.0% in the 4th quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock valued at $227,197,000 after acquiring an additional 5,265,000 shares during the last quarter. Deerfield Management Company L.P. Series C increased its holdings in Dynavax Technologies by 23,990.1% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company's stock worth $66,325,000 after purchasing an additional 5,172,263 shares in the last quarter. Norges Bank acquired a new position in Dynavax Technologies in the 4th quarter worth about $7,762,000. Invesco Ltd. raised its position in Dynavax Technologies by 33.8% in the first quarter. Invesco Ltd. now owns 2,207,631 shares of the biopharmaceutical company's stock valued at $28,633,000 after purchasing an additional 558,046 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its stake in shares of Dynavax Technologies by 34.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company's stock valued at $24,497,000 after purchasing an additional 486,981 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company's stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.